M&R Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $257K | Hold |
2,233
| – | – | 0.06% | 121 |
|
|
2024
Q2 | $238K | Sell |
2,233
-1,075
| -32% | -$108K | 0.06% | 119 |
|
|
2024
Q1 | $320K | Sell |
3,308
-400
| -11% | -$41K | 0.08% | 99 |
|
|
2023
Q4 | $374K | Buy |
3,708
+58
| +2% | +$5.6K | 0.09% | 100 |
|
|
2023
Q3 | $372K | Sell |
3,650
-400
| -10% | -$40.6K | 0.1% | 104 |
|
|
2023
Q2 | $409K | Hold |
4,050
| – | – | 0.11% | 91 |
|
|
2023
Q1 | $373K | Hold |
4,050
| – | – | 0.1% | 100 |
|
|
2022
Q4 | $367K | Hold |
4,050
| – | – | 0.1% | 101 |
|
|
2022
Q3 | $307K | Hold |
4,050
| – | – | 0.09% | 110 |
|
|
2022
Q2 | $342K | Buy |
4,050
+3,500
| +636% | +$307K | 0.09% | 108 |
|
|
2022
Q1 | $48K | Hold |
550
| – | – | 0.01% | 238 |
|
|
2021
Q4 | $48K | Hold |
550
| – | – | 0.01% | 238 |
|
|
2021
Q3 | $44K | Sell |
550
-125
| -19% | -$11.2K | 0.01% | 239 |
|
|
2021
Q2 | $61K | Hold |
675
| – | – | 0.01% | 225 |
|
|
2021
Q1 | $57K | Sell |
675
-318
| -32% | -$28.5K | 0.01% | 213 |
|
|
2020
Q4 | $93K | Hold |
993
| – | – | 0.02% | 206 |
|
|
2020
Q3 | $86K | Sell |
993
-67
| -6% | -$5.8K | 0.02% | 204 |
|
|
2020
Q2 | $92K | Sell |
1,060
-122
| -10% | -$10.5K | 0.02% | 192 |
|
|
2020
Q1 | $97K | Buy |
1,182
+4
| +0.3% | +$357 | 0.03% | 196 |
|
|
2019
Q4 | $111K | Sell |
1,178
-100
| -8% | -$8.97K | 0.02% | 202 |
|
|
2019
Q3 | $111K | Buy |
1,278
+33
| +3% | +$2.96K | 0.03% | 207 |
|
|
2019
Q2 | $113K | Sell |
1,245
-243
| -16% | -$20.6K | 0.03% | 208 |
|
|
2019
Q1 | $108K | Buy |
1,488
+3
| +0.2% | +$241 | 0.02% | 215 |
|
|
2018
Q4 | $114K | Sell |
1,485
-74
| -5% | -$5.76K | 0.03% | 202 |
|
|
2018
Q3 | $120K | Sell |
1,559
-140
| -8% | -$10.3K | 0.03% | 213 |
|
|
2018
Q2 | $115K | Buy |
1,699
+5
| +0.3% | +$345 | 0.03% | 215 |
|
|
2018
Q1 | $122K | Buy |
1,694
+84
| +5% | +$6.39K | 0.03% | 221 |
|
|
2017
Q4 | $121K | Hold |
1,610
| – | – | 0.03% | 223 |
|
|
2017
Q3 | $123K | Hold |
1,610
| – | – | 0.03% | 221 |
|
|
2017
Q2 | $120K | Sell |
1,610
-53
| -3% | -$3.76K | 0.03% | 225 |
|
|
2017
Q1 | $110K | Hold |
1,663
| – | – | 0.03% | 223 |
|
|
2016
Q4 | $108K | Hold |
1,663
| – | – | 0.03% | 213 |
|
|
2016
Q3 | $117K | Hold |
1,663
| – | – | 0.03% | 200 |
|
|
2016
Q2 | $122K | Buy |
+1,663
| New | +$115K | 0.04% | 199 |
|
Other funds holding NVS
M&R Capital Management's NVS Position: Q3 2024 in Review
M&R Capital Management held its Novartis (NVS) position steady in Q3 2024 at 2,233 shares worth $257K. The position accounts for 0.06% of the portfolio, ranked #121.
M&R Capital Management first reported a position in NVS in Q2 2016 and has held it in 34 quarters since. The position peaked at $409K in Q2 2023. 1,312 funds tracked by Wall St. Rank hold NVS as of Q3 2024.
- M&R Capital Management held 2,233 shares of Novartis worth $257K as of Q3 2024.
- M&R Capital Management left its Novartis share count unchanged in Q3 2024.
- Novartis made up 0.06% of M&R Capital Management's portfolio in Q3 2024, its #121 holding.
- M&R Capital Management first reported a position in Novartis in Q2 2016 and has held it in 34 quarters since.
- M&R Capital Management's Novartis position peaked at $409K in Q2 2023.
- 1,312 funds tracked by Wall St. Rank held Novartis as of Q3 2024.
Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.